Writing stories of life

to advance science

News

07.12.2016 | Press Release

Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with ALS

01.09.2016 | Company News

Aducanumab Granted FDA Fast Track Designation and Recent Interim Analysis from PRIME Consistent with Results Previously Reported

31.08.2016 | Press Release

Early Results Show Aducanumab Removes Amyloid Plaques in Patients with Alzheimer's Disease

01.06.2016 | Company News

Aducanumab accepted into EMA's PRIME Program

03.02.2016 | Company News

BIIB076 (anti-tau mAb) moving into pre-IND toxicology studies

10.11.2015 | Company News

Neurimmune’s data on its broadly neutralizing human monoclonal JC polyomavirus VP1–specific antibodies as candidate therapeutics for PML published in Science Translational Medicine

27.10.2015 | Company News

Roger Nitsch honored at Alzheimer's translation and therapeutic panel and luncheon by the American Federation for Aging Research (AFAR)

08.09.2015 | Press Release

Neurimmune Receives Major Development Milestone upon Initiation of Global Phase 3 Studies with Aducanumab for Early Alzheimer’s Disease

28.07.2015 | Company News

Ramot at Tel Aviv University Ltd. and Neurimmune Announce Sponsored Research Agreement for Alzheimer’s Disease Treatment

22.07.2015 | Company News

Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015

02.07.2015 | Company News

BIIB054 reached significant milestone

20.03.2015 | Press Release

BIOGEN IDEC PRESENTS POSITIVE INTERIM RESULTS FROM PHASE 1B STUDY AT 2015 AD/PD CONFERENCE

12.01.2015 | Company News

Aducanumab (BIIB037) showed significant time and dose dependent reduction of beta amyloid in the brain of AD patients

05.01.2015 | Company News

Christoph Hock nominated as VP at the University of Zurich

11.12.2014 | Company News

Aducanumab (BIIB037) for the treatment of Alzheimer’s disease reduced brain beta-amyloid levels in a Phase 1b trial

Your web browser is out of date

Update your browser for more security, speed and the best experience.

Update my browser Continue